Visceral fat accumulation in PCOS patients is linked to early signs of cardiovascular disease and may serve as a prognostic and therapeutic target.
Answers are grounded in this paper and cite their sources.
May inform PCOS risk stratification but should not change practice; leaves open need for prospective validation of visceral fat targeting.
Polycystic ovary syndrome (PCOS) is considered a sex-specific form of the metabolic syndrome (MetS). Visceral obesity is one of the main diagnostic criteria for the MetS. Patients with MetS have a significantly higher risk for cardiovascular disease (CVD). PCOS is the most common endocrine-metabolic disease of reproductive-age women and PCOS patients are predisposed to an androgen adiposity phenotype, characterized by a prevalent fat accumulation in the abdominal area, and by insulin resistance. PCOS women are exposed to a cluster of metabolic abnormalities and cardiovascular risk factors from a young age, and therefore PCOS patients might represent a high-risk group for developing early-onset CVD. Early signs of CVD have been reported in PCOS patients and correlated to the amount of visceral fat. Visceral fat might represent a new prognostic and therapeutic target to define the cardiovascular risk profile and prevent CVD in PCOS patients.
No takes yet. Share an insight, caveat, or question.
Cascella et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: